Eucomed waits on Japanese pricing response:
This article was originally published in Clinica
Executive Summary
Eucomed still awaits a response from the office of the Japanese health minister Chikara Sakaguchi on whether the Japanese are prepared to show flexibility over the introduction of reference pricing for three categories on medical devices (see Clinica No 994, p 4). The Brussels-based European industry association wrote to the ministry in January in a bid to deflect it from its course of basing local prices on those of a sample of foreign countries. The association is now reflecting on whether to approach DG Trade and complain over what could be perceived as discriminatory action. It says the issue will probably get a fuller airing later this year when DG External Relations revisits its annual Japanese cross-sectoral debate on trade deregulation.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.